However, as ∼5% of all colon cancers do overexpress HER2 both in the primary lesion and the corresponding metastasis, HER2-targeted therapy with trastuzumab may still be a treatment option for ∼60,000 patients worldwide each year 25. This evidence concerns the gene ERBB2 and malignant colon neoplasm.